News & Events
-
Locust Walk RNA Innovation Conference
When: May. 9th, 2023
Where: VirtualAnima Biotech has been invited to give a presentation during the Locust Walk RNA innovation event as part of the RNA-Targeting SMOLs track of the Conference held virtually on May 9th. Our chief scientific officer and co-founder, Iris Alroy Ph.D., will give a presentation titled, “Advancing mRNA Lightning™ for the discovery of small molecule mRNA modulators and their mechanisms of action using phenotypic screening and AI driven MOA elucidation” from 1:20 – 1:40 AM ET.
-
Endpoints Webinar | Exposing hidden targets within the mRNA regulation space
When: May. 3rd, 2023
Join our Co-Founder and Chief Scientific Officer, Iris Alroy, Ph.D. as she and other experts delve into the regulatory mechanisms that oversee mRNA translation and how the latest advancements in mRNA regulation research have identified emerging targets for drug discovery and therapeutic intervention.
-
4th Annual RNA-Targeting Small Molecule Drugs hosted by CHI as part of the 18th Annual Drug Discovery Event
When: Apr. 10th, 2023 to Apr. 13th, 2023
Where: San Diego, CA & VirtualAnima Biotech has been invited to give a presentation during the 18th Annual Drug Discovery Chemistry as part of the RNA-Targeting Small Molecule Drugs track of the Conference held from April 10th to April 13th, 2023 in San Diego, CA and virtually. Our chief scientific officer and co-founder, Iris Alroy Ph.D., will give a presentation titled, “Discovery of Small Molecule mRNA Modulators Using Phenotypic Screening with AI-Driven MoA Elucidation” on Tuesday, April 11, 2023 from 8:10 – 8:40 AM PDT.
-
American Chemical Society Spring Meeting (ACS 2023)
When: Mar. 26th, 2023 to Mar. 30th, 2023
Where: Indianapolis, IN & HybridAnima Biotech has been invited to give a presentation during the ACS Spring 2023 Meeting held in Indianapolis, IN and virtually. Our chief scientific officer and co-founder, Iris Alroy Ph.D., will present a talk titled “mRNA translation regulation: Novel targets in drug discovery,” during the “Lost in Translation? Targeting Protein Synthesis as a Therapeutic Strategy” session. Dr. Alroy’s oral presentation takes place on Monday, March 27, 2023 at 4:00 p.m. ET.
-
LSX RNA Leaders Europe Congress
When: Mar. 15th, 2023 to Mar. 16th, 2023
Where: Basel, SwitzerlandAnima Biotech has been invited to give a presentation at the RNA Leaders Congress in Basel Switzerland. Our head of early discovery, Yoni Sheinberger, Ph.D., will give a talk titled, “mRNA Lighting platform | Discovery of mRNA biology modulators and their mechanisms of action” on Mar. 15th at 5:00 PM CET during the “Targeting RNA with Small Molecules” session. Dr. Sheinberger will discuss our proprietary mRNA Lightning platform and how Anima is identifying active compounds and their mechanisms of action.
-
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets
When: Jan. 10th, 2023
AbbVie (NYSE: ABBV), and Anima Biotech (Anima), today announced a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology. Anima will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets providing AbbVie exclusive rights to license and further develop and commercialize the programs.
“This collaboration will give AbbVie access to Anima’s leading technology platform and deep expertise in mRNA biology and will help further strengthen AbbVie’s world class capabilities in discovering and developing drugs to make a difference in patient’s lives,” said Jonathon Sedgwick, Ph.D., vice president and global head of discovery research, AbbVie. “Modulating mRNA biology with small molecules is a new approach and has the potential to address ‘undruggable’ targets with implications across multiple therapy areas.”
”Anima’s differentiated approach in the field of small molecule mRNA drugs combines phenotypic screening with AI-driven elucidation of the mechanisms of action. The power of our mRNA Lightning platform is validated by our multiple partnerships and a growing internal pipeline,” said Yochi Slonim, co-founder and chief executive officer, Anima. “We are excited to partner with AbbVie, a recognized global leader in Oncology and Immunology, and are looking forward to start working with their excellent scientific team in a close collaboration.”
Under the terms of the agreement, Anima will receive an upfront payment of $42 million and may be eligible to receive up to $540 million in option fees and research and development milestones in the aggregate across the three targets, with potential for further commercial milestones as well as tiered royalties on net sales. AbbVie has an option to expand the collaboration with up to three additional targets under the same terms as the initial collaboration, which may increase the potential value of the collaboration.
-
Biotech Showcase 2023
When: Jan. 10th, 2023 to Jan. 11th, 2023
Where: San Francisco, CAAnima Biotech will be attending this year’s Biotech Showcase and is looking forward to connecting with other industry experts. Our chief business officer, Kevin Pong, Ph.D., will give a corporate presentation on Jan. 9th at 9:45 A.M. PST highlighting our unique approach to the discovery of small molecule mRNA drugs.
-
5th RNA Targeting Drug Development Summit
When: Dec. 13th, 2022 to Dec. 15th, 2022
Where: Boston, MAAnima Biotech has been invited to participate in a panel discussion and presentation at the 5th RNA Targeting Drug Development Summit. Our chief business officer, Kevin Pong, Ph.D., will participate in the Biopharma & Investment Partnerships panel – Exploring the Future of RNA Investment & Collaborations Space for Small Molecule on Dec. 14th at 11:50 A.M. Additionally, he will give a talk titled, “mRNA Lightning Platform-Discovery of Small Molecule mRNA Drugs and their Mechanisms of Action” on Dec. 15th at 11:45 A.M. Dr. Pong will highlight our mRNA Lightning platform and how our unique AI driven MOA elucidation and phenotypic screening-based approach has elucidated novel targets that affect mRNA biology.
-
4th NovAliX Virtual Conference
When: Nov. 17th, 2022
Where: DigitalAnima Biotech has been invited to participate in a short session at the 4th NovAliX Virtual Conference. Our co-founder and chief scientific officer, Iris Alroy, Ph.D., will present a short talk titled “Discovery of Small Molecule mRNA Drugs and their Mechanisms of Action using Phenotypic Screening with AI-driven MOA Elucidation” taking place from 11:00 AM to 1:00 PM ET. The talk highlights our mRNA Lightning platform and how our unique AI and phenotypic screening-based approach has elucidated novel targets that affect mRNA biology, driving our lead programs in fibrosis and oncology with demonstrated efficacy in animal and patient-derived models.
-
4th Annual Targeting RNA
When: Oct. 18th, 2022 to Oct. 19th, 2022
Where: Boston, MAAnima Biotech has been invited to participate at the 4th Annual Targeting RNA conference hosted by Cambridge Healthtech Institute. Kevin Pong, Ph.D., Anima’s Chief Business Officer, will give a presentation titled, “Discovery of Small Molecule mRNA Drugs and Their Mechanisms of Action Using Phenotypic Screening with AI-Driven MOA Elucidation” taking place on October 18th at 10:25 a.m. ET.